CoChat

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

Open access
Khan, Omar, Fotheringham, Susan, Wood, Victoria, Stimson, Lindsay, Zhang, Chunlei, Pezzella, Francesco, Duvic, Madeleine, Kerr, David J., La Thangue, Nicholas B. · 2010 · Proceedings of the National Academy of Sciences
Cited by 152

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Histone deacetylase (HDAC) inhibitors are emergent cancer drugs. HR23B is a candidate cancer biomarker identified in a genome-wide loss-of-function screen which influences sensitivity to HDAC inhibitors. Because HDAC inhibitors have found clinical utility in cutaneous T-cell lymphoma (CTCL), we evaluated the role of HR23B in CTCL cells. Our results show that HR23B governs the sensitivity of CTCL cells to HDAC inhibitors. Furthermore, proteasome activity is deregulated in HDAC inhibitor-treated CTCL cells through a mechanism dependent upon HR23B, and HDAC inhibitors sensitize CTCL cells to the effects of proteasome inhibitors. The predictive power of HR23B for clinical response to HDAC inhibitors was investigated through an analysis of a unique collection of CTCL biopsies taken from a phase II clinical trial, where there was a frequent coincidence between HR23B expression and clinical response to HDAC inhibitor. Our study supports the personalized medicine approach for treating cancer and the increasing drive to translate laboratory-based findings into clinical utility.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0913912107

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 152

Metadata

Authors
Khan, O., Fotheringham, S., Wood, V., Stimson, L., Zhang, C., Pezzella, F., Duvic, M., Kerr, D. J., & La Thangue, N. B.
Venue
Proceedings of the National Academy of Sciences
Published
2010-03-22
Volume
107
Issue
14
Pages
6532-6537
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2057358066
Cited by
152
References
5
FWCI
6.73
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. https://app.cochat.ai/papers/10.1073/pnas.0913912107
The paper
Khan, O., Fotheringham, S., Wood, V., Stimson, L., Zhang, C., Pezzella, F., Duvic, M., Kerr, D. J., & La Thangue, N. B. (2010). HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0913912107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.